|15. Switch to a TNFi biologic monotherapy over MTX and a TNFi biologic combination therapy (PICO 19)|Low (109â€“111)|
|Conditional recommendation based on low-quality evidence; may consider MTX and TNFi biologic combination therapy if the patient has severe skin manifestations, has had a partial response to current MTX therapy, has concomitant uveitis (since uveitis may respond to MTX therapy), and if the current TNFi biologic is infliximab or adalimumab.|Conditional recommendation based on low-quality evidence; may consider MTX and TNFi biologic combination therapy if the patient has severe skin manifestations, has had a partial response to current MTX therapy, has concomitant uveitis (since uveitis may respond to MTX therapy), and if the current TNFi biologic is infliximab or adalimumab.|
|16. Switch to an IL-17i biologic monotherapy over MTX and an IL-17i biologic combination therapy (PICO 21)|Very low|